Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026764 (multiple myeloma)
 36,148 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Based on data from the cancer register of the German Democratic Republic established in 1952 and on the official mortality statistics, incidence of and mortality from malignant lymphomas (ICD 200-203) in the GDR are analysed. Age-specific incidence and mortality of Hodgkin's disease show a peak in the age group of 25-30 years and rise steadily from 45 years on up to the highest age. Lymphosarcoma and reticulosarcoma increase slowly from infancy to old age, whereas multiple myeloma is a disease of the elderly and extremely rare before the age of 40. The apparent increase of malignant lymphoma may be due to underregistration at the beginning of the cancer register. In the past years mortality from Hodgkin's disease is slowly decreasing, thus reflecting progress in methods of treatment and results.
 ...
PMID:[Incidence and mortality of malignant lymphomas in the GDR]. 53 15

A hospital-based case-control study was done to examine the hypothesis that persons with a family history of multiple myeloma (MM) or other cancers are at increased risk of multiple myeloma. Study members were 439 cases of multiple myeloma and 1317 matched controls seen at the Duke University Medical Center. Only 3 cases and 4 controls reported multiple myeloma in their families. The relative risk (RR) was 2.3, but the 95% confidence interval (CI) was 0.5-10.1, allowing no firm conclusion about the risk associated with familial MM. A family history of cancer of any type resulted in a relative risk of MM of 1.4 (CI: 1.1-1.8). This association was strongest (RR = 2.5, CI: 1.1-5.3) among young study members (age less than or equal to 49). A family history of hematologic malignancy (ICD 200-208) resulted in a RR of 2.4 (95% CI: 1.4-4.0). The data also suggested that a family history of lung cancer, breast cancer, and genitourinary cancer may be associated with increased risk of myeloma in older persons.
 ...
PMID:Multiple myeloma and family history of cancer. A case-control study. 402 40

After regional media had reported in early 1995 of multiple leukaemia cases in a small community in the state of Schleswig-Holstein, an "Epidemiological Task Force" was asked to review the existing evidence for a possible cluster. The Task Force is a small group appointed in 1994 by the regional Medical Association and the state's ministry of social affairs. It includes five professionals from the fields of environmental toxicology and hygiene, Public Health, epidemiology and cancer pathology. In agreement with the local Public Health administration and the ministry the Task Force organized a retrospective screening of all incident leukaemia, lymphoma and myeloma cases (ICD-9 codes 200-208) within a (5-10 km) around the small community (population on December 31st 1993: 72000) that had occurred after January 1st 1990. Any practising physician (response rate 78%), hospital (100 %), oncological centre (100%), and tumour registry (100%) serving the region were asked to notify all relevant cases to the Task Force. Additionally spontaneous case reports were elicited, and all death certificates from the a.m. time period were screened for by two Public Health administrations. We identified 202 single cases for further analysis. Comparative data for the entire region and single communities came from two cancer registries, the Danish and that of the state of Saarland/FRG, and allowed for calculating the expected number of cases by indirect standardisation. While Hodgkin's lymphomas and myelomas were (insignificantly) less frequent than expected, an excess of non-Hodgkin's lymphomas and leukaemias (all types combined) was observed. Standardised incidence ratios for the whole region varied between 1.54 and 1.68 with significant and consistent increases only for the group of leukaemias among adults (aged 15+). All results were reported to both the public and administrative/professional bodies together with specific recommendations. The reactions showed a good acceptance of the Task Force and its work.
 ...
PMID:[A leukemia cluster in the Pinneberg district. Results of an incidence study by the epidemiologic task force of the Schleswig-Holstein Medical Association]. 864 98

The annual incidence of non-Hodgkin's lymphomas is increasing by 3 to 4% in different parts of the developed world, while rates for Hodgkin's disease, myelomas and leukemias are more stable. In the case of this group of malignancies, hypothesis generation on risk factors has been limited by the use of the ICD classification in mortality and incidence statistics. We have computed incidence rates in different Italian areas after careful re-classification of diagnoses, and considering specific histotypes (Working Formulation for NHL, Rye's classification for HD). While no particularly interesting pattern is suggested for Hodgkin's disease (even after considering specific Rye subgroups), multiple myeloma and leukemias, for non-Hodgkin's lymphomas the high rate in one agricultural area (Forli) was mainly due to the A sub-group in the Working Formulation (low-grade). In a heavily industrialized area (Varese), the high incidence rate was at least partly explained by a higher proportion of cases classified in the G sub-group (intermediate grade). Excesses of non-Hodgkin's lymphomas have been observed in populations exposed to phenoxy-acetic-acid herbicides, to insecticides and to organic solvents. One can hypothesize that different risk factors act on different stem cells and induce lymphoid malignancies belonging to different histologic sub-types.
 ...
PMID:Incidence rates of leukemias, lymphomas and myelomas in Italy: geographic distribution and NHL histotypes. 890 Apr 20

This is a further update of a cohort mortality study of 2795 male workers employed at least 6 months between 1942 and 1994 at a 1,3-butadiene facility. Earlier reports on this cohort found a statistically significant deficit for all causes of death and lower than expected mortality for most leading causes of death. Prior reports noted an excess of deaths from lymphosarcoma primarily in those employed less than 10 years, first employed before 1946, and employed in jobs with the potential for daily exposure to butadiene (BD). There was a nonsignificant elevation for leukemia in persons potentially exposed to BD on an intermittent basis. The purpose of this update was to examine the patterns of mortality with four additional years of follow-up. Persons who had become eligible since the cohort was last updated through 1990 were also added. A total of 1222 deaths were identified, and death certificates were obtained for all but 20 of the deaths (1.6%). The standardized mortality ratio (SMR) for all causes of death is 88 (95% confidence interval (CI) = 83-93), and for all cancer, the SMR is 92 (95% CI = 82-104). There were 42 deaths from lymphohematopoietic cancers (LHC) with 28.6 expected (SMR = 147, 95% CI = 106-198), 9 observed vs. 4.7 expected deaths for lymphosarcoma (SMR = 191, 95% CI = 87-364), 13 observed vs. 11.5 expected deaths for leukemia (SMR = 113, 95% CI = 60-193), and 15 observed vs. 9.9 expected deaths from cancer of other lymphatic tissue (SMR = 152, 95% CI = 85-250). Subcohort analyses showed that the elevated risk of all LHC and its subcategories was restricted to persons who were first employed before 1950. As an adjunct to the SMR analyses, modeling was done using a qualitative cumulative exposure score as a time-dependent explanatory variable for, (1) all LHC (ICD 200-209); (2) lymphosarcoma (ICD 200); (3) lymphosarcoma and other lymphoma (ICD 200, 202); (4) multiple myeloma (ICD 203); and (5) leukemia (ICD 204-207). The cumulative exposure score was not significantly associated with any of these cancers. Cancer risk was found to increase with age for all of the LHC groups analyzed, except for lymphosarcoma. Similarly, cancer risk was found to increase with age-at-hire for all of the LHC groups except for multiple myeloma.
 ...
PMID:Mortality update of butadiene production workers. 890 96

Non-Hodgkin's lymphoma (NHL) is not a uniform disease entity, and in order to investigate the reported changes in incidence we have set up a study in seven population-based cancer registries in Europe. The study is designed to look at changes in the incidence of total NHL and disease subgroups using standard definitions and methodology. The registries are based in Leeds, Dijon, Kuopio, Odense, Florence, Eindhoven, and Ragussa. The classification system we have used is based on the REAL classification and has utility for epidemiological studies. We have used it to convert data sets which have utilized both local cases and the ICD-O classification. In order to improve data reproducibility, CLL/LL, myeloma/MGUS, lymphoblastic disease, and Hodgkin's disease have been excluded because of the difficulty in defining incident cases accurately. The preliminary results of this study show that there is still an upward trend in incidence rate and that in Yorkshire this is 3% per annum in total NHL. The subgroups which are increasing are extranodal and nodal peripheral T-cell lymphoma. Similar increases in incidence have been reported for the other registries. We conclude that there is a continued upward trend in incidence of NHL, the causes of which are uncertain.
 ...
PMID:Changing trends in the incidence of non-Hodgkin's lymphoma in Europe. Biomed Study Group. 920 41

The killing capacity of extracts from Viscum album L., widely used as an adjuvant in complementary cancer therapy, is dependent on the content of toxic proteins, especially the mistletoe lectins (ML). Although one may expect a homogeneous distribution of 'receptors' for these proteins on the cell surface, the sensitivity of cells to the ML-mediated cytotoxicity obviously differs, as the galNAc-binding ML III in contrast to the gal-binding ML I selectively killed CD8+ lymphocytes with a 'memory' phenotype (CD62Llo), while CD19+ B cells remained almost unaffected. B cells hardly bind ML III but did bind the gal-specific ML I. In accordance with these observations, in leukaemic B cells from patients with B chronic lymphocytic leukaemia and the human IgE-secreting myeloma cell line U-266 a strong induction of apoptosis-associated mitochondrial Apo2.7 molecules was observed after treatment with ML I and less effectively by ML III, while in the leukaemic T cell line Molt-4 both ML were strong inductors of apoptosis. In the light of these findings, the possible impact of ML I- and ML III-rich mistletoe extracts in the treatment of B cell neoplasia has to be carefully investigated.
 ...
PMID:Differential binding of toxic lectins from Viscum album L., ML I and ML III, to human lymphocytes. 1069 16

Age-specific and age-standardized rates (ASR) of registered cancers for nine communities in the U.S.A. (21.8 million inhabitants, mainly white) were obtained from IARC data (1978-82, 1983-87, 1988-92). The percentage of people supplied with "optimally" fluoridated drinking water (FD) obtained from the Fluoridation Census 1985, U.S.A. were used for regression analysis of incidence rates of cancers at thirty six sites (ICD-WHO, 1957). About two-thirds of sites of the body (ICD) were associated positively with FD, but negative associations were noted for lip cancer, melanoma of the skin, and cancers of the prostate and thyroid gland. In digestive organs the stomach showed only limited and small intestine no significant link. However, cancers of the oral cavity and pharynx, colon and rectum, hepato-biliary and urinary organs were positively associated with FD. This was also the case for bone cancers in male, in line with results of rat experiments. Brain tumors and T-cell system Hodgkin's disease, Non-Hodgkin lymphoma, multiple myeloma, melanoma of the skin and monocytic leukaemia were also correlated with FD. Of the 36 sites, 23 were positively significant (63.9%), 9 not significant (25.0%) and 4 negatively significant (11.1%). This may indicate a complexity of mechanisms of action of fluoride in the body, especially in view of the coexising positive and negative correlations with the fluoridation index. The likelihood of fluoride acting as a genetic cause of cancer requires consideration.
 ...
PMID:Regression analysis of cancer incidence rates and water fluoride in the U.S.A. based on IACR/IARC (WHO) data (1978-1992). International Agency for Research on Cancer. 1151 73

Trends in cancer mortality in Switzerland were analysed over the period 1980-2001, on the basis of the World Health Organization database. Appropriately developed correction factors were utilized for the period before 1995, to allow for spurious trends introduced by the change between the 8th and the 10th revisions of the ICD. Steady declines in cancer mortality were observed, particularly from the mid-1980s onwards. Over the last decade, the fall in overall age-standardized (world standard) cancer mortality was 11.1% in men (from 158.1 in 1990-1991 to 140.6/100,000 in 2000-2001) and 7.6% in women (from 91.6 to 84.7/100,000), and the decline was larger in truncated rates from 35 to 64 years (-18.0 and -9.7%). In men, all major tobacco and alcohol neoplasms have declined until the late 1990s but have levelled off over the last few years, reflecting recent trends in alcohol and tobacco consumption. The fall in male lung cancer mortality was 20% over the last decade (from 42.9 to 34.3/100,000). In contrast, lung cancer mortality in women has steadily increased by 38% between 1981 and 1991 and by 47% between 1991 and 2001, to reach 10.7/100,000 at all ages and 18.3 at age 35 to 64, due to increased prevalence of smoking in subsequent generations of Swiss women. Other sites showing substantial declines include stomach and colorectum in both sexes, (cervix) uteri and breast in women. Likewise, prostate cancer showed modest favourable trends after 1995. Steady declines were observed for leukaemias, Hodgkin's disease and testicular cancer, namely, the neoplasms most influenced by therapeutic improvements, while trends in lymphomas and myeloma showed no clear pattern.
 ...
PMID:Trends in cancer mortality in Switzerland, 1980-2001. 1637 23

This study aimed to assess the performance of several algorithms based on hospital diagnoses and the long-term diseases scheme to identify multiple myeloma patients.Potential multiple myeloma patients in 2010 to 2013 were identified using the presence of hospital records with at least 1 main diagnosis code for multiple myeloma (ICD-10 "C90"). Alternative algorithms also considered related and associated diagnoses, combination with long-term conditions, or at least 2 diagnoses. Incident patients were those with no previous "C90" codes in the past 24 or 12 months. The sensitivity, specificity, and positive and negative predictive values (PPVs and NPVs) were computed, using a French cancer registry for the corresponding area and period as the criterion standard.Long-term conditions data extracted concerned 11,559 patients (21,846 for hospital data). The registry contained 125 cases of multiple myeloma. Sensitivity was 70% when using only main hospital diagnoses (specificity 100%, PPV 79%), 76% when also considering related diagnoses (specificity 100%, PPV 74%), and 90% with associated diagnoses included (100% specificity, 64% PPV).In relation with their good performance, selected algorithms can be used to study the benefit and risk of drugs in treated multiple myeloma patients.
 ...
PMID:Identifying multiple myeloma patients using data from the French health insurance databases: Validation using a cancer registry. 2832 5


1 2 Next >>